Chronic Disease
Featured Topics
Lead story
Other featured articles
-
The CBO Report on Medicare and Anti-Obesity Medications Should Not Be the Final Word
The highly anticipated report contains clues on how Congress may come to a different view on medications like Wegovy and Zepbound.
Posted in -
Incentivizing Chronic Disease Prevention and Treatment
Rebalancing the healthcare system to favor prevention and cures can potentially reduce the long-term burden of chronic diseases.
Posted in -
Cross-Sectional and Longitudinal Associations Among Healthcare Costs and Deficit Accumulation
Deficit accumulation frailty tracks well with healthcare costs among adults with type 2 diabetes and overweight or obesity. It may serve as a useful marker to project healthcare needs and as an intermediate outcome in clinical trials.
Posted in -
Cancer Treatment Before and After Physician-Pharmacy Integration
Results of this cohort study indicated that the integration of oncology practices with pharmacies was not associated with significant changes in expenditures or clear patient-centered benefits.
Posted in
About this section
Chronic diseases are among the most preventable and costliest conditions, consuming the overwhelming majority of Medicare resources. The Schaeffer Center assembles leading minds from across disciplines to address this challenge, striving to simplify labyrinthine systems of care and promote healthier outcomes.
Our Experts On Chronic Disease
Our Work In Chronic Disease
-
Study: Integration of Pharmacies with Physician Practices Has Little Impact on Cancer Drug Expenditures
Researchers found a slight increase in use of oral cancer drugs, but no significant change in expenditures on the drugs.
Categorized in -
Association Between Oral Targeted Cancer Drug Net Health Benefit, Uptake, and Spending
Low- net health benefit (NHB) targeted cancer drugs (TCDs) were prescribed less frequently than medium- and high-net NHB TCDs. Total spending on oral TCDs was high and positively associated with NHB.
Categorized in -
Medicare Coverage of Weight Loss Drugs Could Save the U.S. Billions of Dollars
The new weight loss drugs work, and represent huge value in treating obesity. Even though they are expensive, broader access to them via Medicare would end up saving the U.S. money.
Categorized in -
Seminar Series – Boris Vabson
Boris Vabson is a research faculty member at Harvard Medical School. His academic research focuses on health insurance payment systems and markets. He is also a nonresident fellow at the USC-Schaeffer Center and a nonresident fellow in health policy at the American Enterprise Institute.
-
Seminar Series – Jorge Luis Garcia
Jorge Luis Garcia, PhD, is an applied micro-economist working at the intersection of labor and development economics. His work aims to quantify the economic fundamentals underlying the causal effects of major policies to inform their design and evaluation.
-
Response to Sen. Cassidy’s Request for Information on Improving Americans’ Access to Gene Therapies
Schaeffer experts submitted a comment letter responding to a request for information from stakeholders about improving access to cell and gene therapies for ultra-rare diseases.
Categorized in